A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases. - VACCIMM

Charité - Universitätsmedizin Berlin0 个研究点目标入组 250 人开始时间: 2021年4月30日最近更新: 2021年6月7日

试验速览

暂无简介。

•1. written consent for study participation.
•2. if study entry after first vaccination: written informed consent for analysis of any archived blood samples.
•3. males and females = 18 years of age.
•4. either arm 1 (AIRD patients): diagnosis of rheumatic autoimmune disease or arm 2 (control group): no diagnosis of rheumatic autoimmune disease.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 2000
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. persons not capable of giving consent
•2. serious illnesses which, in the opinion of the investigator, preclude inclusion or continued observation (for example, tumor diseases requiring intensive chemotherapy).
•3. individuals who are unable or unwilling to undergo multiple venipunctures because he/she is intolerant or has poor venous conditions.
•4. persons who are admitted to an institution by court order or by order of the authorities.

发起方